NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Neurogene Inc. (NGNE) Stock Analysis

Neurogene Inc. (NGNE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NGNE

$26.08

+$0.68 (+2.68%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NGNE with… →

NGNE Key Statistics

As of Oct 21, 2026
Trading
Open
$25.52
Previous Close
$25.40
Day's Range
25.11–26.94
52-Week Range
15.93–43.66
Volume
588.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.09
Valuation
Market Cap
$521.90M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.04
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$90.35M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
20.01M
1-Year Return
−17.39%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
269.73K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NGNE closed at $26.08, −17.39% over 1 year.

Neurogene Inc. (NGNE) has a market capitalization of $521.90M.

In fiscal 2025, NGNE reported revenue of $0.00.

NGNE Stock Return by Calendar Year

Neurogene Inc. (NGNE) 10-year return: what $10,000 became

1 year
$10,000 $8,261
−17.39%
5 years
$10,000 $1,860
−81.40%
10 years
$10,000 $1,216
−87.84%

If you had invested $10,000 in Neurogene Inc. (NGNE) 10 years ago, at the close on October 21, 2016, it would have been worth $1,216 at the close on October 21, 2026: −87.84% in total, −19.00% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+26.60%
2025−9.89%
2024+17.96%
2023+90.37%
2022−89.44%
2021−65.82%
2020+14.45%
2019+470.37%
2018−81.63%
2017−28.77%
2016 (partial year)+80.63%

As of October 21, 2026.

NGNE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$90.35M—
2024$925.00K−$75.14M−8,123.7%
2023$0.00−$36.32M—
2022$0.00−$55.19M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$103.33M−$90.35M—
2024$925.00K—−$82.61M−$75.14M−8,123.7%
2023$0.00—−$55.58M−$36.32M—
2022$0.00—−$56.52M−$55.19M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Neurogene Inc. (NGNE) is capitalised at $521.90M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 131 employees.

The most recent close on file for NGNE is $26.08, dated October 21, 2026. That is +$0.68 (+2.68%) against the previous close. The 52-week range on file runs from $15.93 to $43.66. The latest close sits 63.72% above that 52-week low.

Financial Health

In fiscal 2025, Neurogene Inc. reported revenue of $0.00. Against the prior fiscal year total of $925.00K, that is a change of −100.00%. The same year closed with a net loss of $90.35M. Trailing earnings per share are −5.04.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 2.09. Daily returns over the trailing 10 years annualize to a volatility of 87.79%. The trailing one-year total return is −17.39%. Measured over 10 years, that is −19.00% a year compounded.

Growth & Income

The record shows no dividend for NGNE.

Across the complete calendar years on file, 2019 returned +470.37% and 2022 returned −89.44%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the total return is +26.60%.

Peer Comparison

Neurogene Inc. (NGNE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Neurogene Inc. NGNE $521.90M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Neurogene Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Neurogene Inc.

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Visit website →